Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $58.6, along ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $493.2, a high estimate of ...
Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...
International Paper's acquisition of DS Smith strengthens its global footprint, despite a 2.3% Q4 revenue decline, leading me ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback